全部文献期刊学位论文会议报纸专利标准年鉴图书|学者科研项目
中外文文献  中文文献  外文文献
作者:... Anne Dørum , Per E. Lønning , Stian Knappskog
来源:[J].BMC Cancer(IF 3.333), 2017, Vol.17 (1)Springer
摘要:The del1518 (rs3730485) polymorphism is an in/del variant in the MDM2 promoter P1. The variant is in complete linkage disequilibrium with MDM2 SNP309 (rs2279744) and has previously been found associated with an increased risk of colon cancer. In this study we assessed the impact ...
作者:... Jan Inge Øvrebø , Per E. Lønning , Stian Knappskog
来源:[J].BMC Cell Biology(IF 2.808), 2017, Vol.18 (1)Springer
摘要:The murine double minute 2 (MDM2) is an oncogene and a negative regulator of the tumor suppressor protein p53. MDM2 is known to be amplified in numerous human cancers, and upregulation of MDM2 is considered to be an alternative mechanism of p53 inactivation. The presence of many ...
作者:... Jan Inge Øvrebø , Per E. Lønning , Stian Knappskog
来源:[J].Translational Oncology(IF 3.393), 2017, Vol.10 (5), pp.806-817Elsevier
摘要:Abstract(#br)BACKGROUND: MDM2 is a negative regulator of p53 and is upregulated in numerous human cancers. While different MDM2 splice variants have been observed in both normal tissues and malignant cells, their functions are poorly understood. METHODS: We evaluated the eff...
作者:Per E. Lønning , William D. Foulkes
来源:[J].Breast Cancer Research and Treatment(IF 4.469), 2012, Vol.133 (2), pp.501-510Springer
摘要:Abstract(#br)Angiogenesis is important for the growth and spread of malignant tumors, and anti-angiogenesis treatment is currently being evaluated for breast cancer and other tumors. Although microvessel density is the most commonly used tissue-based marker of tumor associated an...
作者:Per E. Lønning , Jürgen Geisler
来源:[J].Journal of Steroid Biochemistry and Molecular Biology(IF 3.984), 2007, Vol.106 (1), pp.55-61Elsevier
摘要:Abstract(#br)With costs of health care in general and for cancer therapy in particular escalating due to implementation of novel compounds, there is an increasing focus on therapy costs in most countries. A common way of assessing therapeutic utility versus cost is by assess...
作者:Per E. Lønning , Jürgen Geisler
来源:[J].Journal of Steroid Biochemistry and Molecular Biology(IF 3.984), 2005, Vol.95 (1), pp.137-142Elsevier
摘要:Abstract(#br)Novel, third-generation aromatase inhibitors are currently implemented for treatment of postmenopausal breast cancer in the metastatic and adjuvant setting and, potentially, for breast cancer prevention. Introduction of novel therapeutic strategies to large patient g...
作者:Per E. Lønning , Jürgen Geisler
来源:[J].Journal of Steroid Biochemistry and Molecular Biology(IF 3.984), 2007, Vol.108 (3), pp.196-202Elsevier
摘要:Abstract(#br)The implementation of aromatase inhibitors for treatment of early and metastatic breast cancer has been one of the major improvements in endocrine therapy of breast cancer. Measurement of endocrine effects of aromatase inhibition in vivo has been a major tool in...
作者:Per E. Lønning
来源:[J].Clinical Breast Cancer(IF 2.422), 2000, Vol.1, pp.S28-S33Elsevier
摘要:Abstract(#br)Exemestane is a novel, potent, and specific third-generation aromatase inactivator developed for breast cancer therapy. The drug is effective in patients with metastatic disease failing tamoxifen alone or tamoxifen followed by megestrol acetate or a nonsteroidal arom...
作者:... Michael Tally , Kerstin Hall , Per E. Lønning
来源:[J].Journal of Steroid Biochemistry and Molecular Biology(IF 3.984), 1996, Vol.57 (3), pp.167-171Elsevier
摘要:Abstract(#br)The influence of the novel anti-estrogen droloxifene on the insulin-like growth factor (IGF) system in plasma was studied in two groups of breast cancer patients receiving droloxifene 40 mg o.d. (group 1, n = 6) or 100 mg o.d. (group 2, n = 7). Fasting blood samples ...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×